In this study, twenty known compounds were isolated from Houttuynia cordata Thunb., including four megastigmanes (1‒4), four phenolics (5, 6, 9, and 10), one tetrahydro-2-one derivative (12), four coumarins (7, 13, 14, and 16), six caffeic acid derivatives (8, 11, 15, 17, 18, and 19), and one triterpenoid (20). Their chemical structures were established using NMR spectra and comparison with literature. The anti-diabetic activity of the isolated compounds was assessed by investigating their inhibitory effects on protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase. The results revealed that ginnalin A (10) and 3-(4′-hydroxyphenyl)-2-propenoic acid (4′′-carboxyl)-phenyl ester (13) exhibited significant inhibitory effects on both PTP1B and α-glucosidase with IC 50 values of 7.9 ‒ 37.6 and 13.9 ‒ 31.9 μM, respectively. In the kinetic study, these two compounds showed noncompetitive-type PTP1B and α-glucosidase inhibition, with K i values of 35.6 and 7.3 μM for PTP1B and 13.9 and 31.0 μM for α-glucosidase, respectively. These findings highlight the potential of the isolated compounds as candidates for the development of novel therapeutic agents for diabetes.

Globally, providing evidence on the economic burden of chronic obstructive pulmonary disease (COPD) is becoming essential as it assists the health authorities to efficiently allocate resources. This study aimed to summarize the literature on economic burden evidence for COPD from 1990 to 2019. This study examined the economic burden of COPD through a systematic review of studies from 1990 to 2019. A search was done in online databases, including Web of Science, PubMed/Medline, Scopus, and the Cochrane Library. After screening 12,734 studies, 43 articles that met the inclusion criteria were identified. General study information and data on direct, indirect, and intangible costs were extracted and converted to 2018 international dollars (Int$). Findings revealed that the total direct costs ranged from Int$ 52.08 (India) to Int$ 13,776.33 (Canada) across 16 studies, with drug costs rannging from Int$ 70.07 (Vietnam) to Int$ 8,706.9 (China) in 11 studies. Eight studies explored indirect costs, while one highlighted caregivers’ direct costs at approximately Int$ 1,207.8 (Greece). This study underscores the limited research on COPD caregivers’ economic burdens, particularly in developing countries, emphasizing the importance of increased research support, particularly in high-resource settings. This study provides information about the demographics and economic burden of COPD from 1990 to 2019. More strategies to reduce the frequency of hospital admissions and acute care services should be implemented to improve the quality of COPD patients’ lives and reduce the disease’s rising economic burden.